Global Familial Amyloid Polyneuropathy Therapeutic Market Growth (Status and Outlook) 2025-2031

The global Familial Amyloid Polyneuropathy Therapeutic market size is predicted to grow from US$ 1590 million in 2025 to US$ 2272 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).

The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.

Here are some key points related to the global FAP therapeutic market:

Market Overview: The market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.

Disease-Modifying Therapies: The development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.

TTR Stabilizers: TTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.

RNA Interference (RNAi) Therapies: RNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.

Liver Transplantation: In some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.

Geographic Considerations: The global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.

Ongoing Research and Development: The FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.

LPI (LP Information)' newest research report, the “Familial Amyloid Polyneuropathy Therapeutic Industry Forecast” looks at past sales and reviews total world Familial Amyloid Polyneuropathy Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Familial Amyloid Polyneuropathy Therapeutic sales for 2025 through 2031. With Familial Amyloid Polyneuropathy Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Familial Amyloid Polyneuropathy Therapeutic industry.

This Insight Report provides a comprehensive analysis of the global Familial Amyloid Polyneuropathy Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Familial Amyloid Polyneuropathy Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Familial Amyloid Polyneuropathy Therapeutic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Familial Amyloid Polyneuropathy Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Familial Amyloid Polyneuropathy Therapeutic.

This report presents a comprehensive overview, market shares, and growth opportunities of Familial Amyloid Polyneuropathy Therapeutic market by product type, application, key players and key regions and countries.

Segmentation by Type:
Inotersen
Tafamidis
Patisiran
Others

Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Prothena Corporation
Eidos Therapeutics
FoldRx Pharmaceuticals
Akcea Therapeutics
GlaxoSmithKline (GSK)
Greenovation Biotech GmbH

Please note: The report will take approximately 2 business days to prepare and deliver.